Kidney function testing sits at the heart of preventive medicine, yet the standard blood marker most clinicians rely on — creatinine — may be leaving a meaningful portion of high-risk patients undetected. A large Swedish cohort study published in JAMA now offers some of the most rigorous comparative evidence to date on which filtration metrics best predict who will suffer serious downstream harm.
The research evaluated four distinct approaches to measuring glomerular filtration rate (GFR) — the gold-standard directly measured GFR, creatinine-based estimated GFR (eGFR-Cr), cystatin C-based estimated GFR (eGFR-CysC), and a combined creatinine-cystatin C estimate — against major clinical endpoints including cardiovascular events, kidney failure, and all-cause mortality in a large Swedish patient population. Across outcomes, eGFR derived from cystatin C — either alone or in combination with creatinine — tracked more closely with directly measured GFR and showed stronger associations with adverse health outcomes than creatinine-based estimates alone.
This finding matters because creatinine is disproportionately influenced by muscle mass, meaning younger adults, athletes, and individuals with high lean body mass may appear to have better kidney function than they actually do — a form of systematic misclassification. Cystatin C, a protein produced by virtually all nucleated cells and filtered freely by the glomerulus, is far less susceptible to this confounding. The clinical research community has debated its routine adoption for years, but implementation has lagged partly due to cost and standardization concerns. A study of this scale, anchored in a nationally representative Swedish registry and published in JAMA, carries substantial weight toward shifting clinical guidelines. The primary limitation is its observational design — confounding by indication remains possible, and Swedish population demographics may limit generalizability to more ethnically diverse healthcare settings. Still, this is confirmatory evidence with large sample strength, likely to accelerate cystatin C's integration into standard kidney function panels.